xRead - Globus and Chronic Cough (April 2024)

Wamkpah et al.

Page 23

Author Manuscript Author Manuscript Author Manuscript Author Manuscript # Patients enrolled; completed therapy (males/ females) Average age in years Comparator Treatment duration Primary outcome measure LCQ

Secondary outcome measure(s)

Cough severity VAS PFTs FeNO HARQ LCQ

Sputum examination PFTs FeNO

24-hr cough frequency (coughs/hr)

Cough severity VAS LCQ

Cough symptom score Capsaicin cough challenge GerdQ

Cough severity VAS

Urge-to-cough VAS HARQ

Cough frequency (coughs/hr)

Daytime cough

frequency (coughs/hr)

24-hr and nighttime cough frequency (coughs/hr) LCQ

Cough severity VAS

Cough global rating of change

Cough severity VAS

Daily cough symptom diary LCQ

62 Mast cell inhibitor: sodium cromoglicate (PA101) 40 mg/inhalation TID Placebo inhaler TID 2 weeks Daytime cough frequency (coughs/hr) 62 Leukotriene antagonist: Oral corticosteroid prednisolone 20 mg daily (15) 2 weeks 24-hr cough frequency (coughs/hr) E: 62.7

12 weeks Daytime cough frequency

(coughs/hr)

12 weeks Successful rate of cough resolution

ATP, citric

acid, distilled

water cough challenges

2 weeks 24-hour cough frequency

(coughs/hr)

12 weeks Daytime cough frequency

(coughs/hr)

16 days Daytime cough frequency

(coughs/hr)

6 months LCQ

61 P2X3 inhibitor: gefapixant 100 mg Placebo oral tablet Single dose Capsaicin, E: 54.5 C: 57.2

Neuromodulator:

Neuromoduiator

intervention (n patients)

Placebo oral tablet daily (93)

gabapentin 900 mg daily (117)

Placebo oral tablet BID (12)

Placebo oral tablet BID (63)

Placebo oral tablet BID

gabapentin maximum 1800 mg daily (19)

Neuromodulator: baclofen

P2X3 inhibitor: gefapixant

60.2 P2X3 inhibitor: gefapixant

Study 1: 63.2 Study 2: 60.2 P2X3 inhibitor: gefapixant

NK-1 inhibitor: serlopitant

61 Tricyclic antidepressant: amitriptyline or

Experimental

intervention (n patients)

montelukast 10 mg qHS (35)

5 mg daily (92)

60 mg daily (117)

45 mg BID (11)

7.5 mg BID (64)

20 mg BID (63)

50 mg BID (63)

Study 1: 50 mg/100

mg/150 mg/200 mg BID, dose escalated every 4 days

Study 2: 7.5 mg/15 mg/30 mg/50 mg BID, dose escalated every 4 days

nortriptyline maximum

C: 62.6

E: 45.2

C: 47.5

28; 27

(6/21)

(17/32)

(41/135)

(89/145)

24; 24

(3/21)

(6/17)

(60/193)

Study 1: 29; 27

Study 2: 30; 29 (10/49)

28;

28(12/16)

number (year) Location Study design London, Crossover RCT

Parallel RCT 50; 47

Parallel RCT 234; 217 Crossover RCT

NCT03482713 (2019) Japan Parallel RCT 23; 23 Smith et al (2020) Manchester,

Parallel RCT 253; 222

Crossover RCT

Prospective cohort

England, UK

Cottingham,

England, UK

UK, USA Parallel RCT 185; 176 Shanghai, China Cottingham, England, UK

England, UK

Manchester,

England, UK

Cleveland,

OH, USA

Birring et al (2017)

Sadeghi et al (2018)

NCT03282591 (2018)

Dong et al (2019)

Morice et al (2019)

Smith et al (2020)

Bowen et al (2018)

Author or

clinical trial

Laryngoscope . Author manuscript; available in PMC 2022 January 01.